Clinical trials
High Grade Glioma (III or IV) clinical trials
Below are recruiting high grade glioma (iii or iv) clinical trials, each written for real people, not researchers. We’re tracking 1,259 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06883747RecruitingEarly Phase 1
Study of BMS-986504 for recurrent brain tumor
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
Phoenix, ArizonaAges 18 years+ - NCT06889493RecruitingPhase 1
SVV-001 plus immunotherapy for neuroendocrine cancers
This trial tests a new virus-based treatment (SVV-001) combined with two immunotherapy drugs (nivolumab and ipilimumab) for people with advanced neuroendocrine cancers that have gotten worse after at least one prior treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Miami, FloridaAges 18 years+ - NCT06889688RecruitingPhase 3
New drug combo vs. chemo for advanced triple-negative breast cancer
This trial tests a new combination of three drugs (camrelizumab, apatinib, and eribulin) against the standard chemotherapy chosen by your doctor. It's for people with advanced triple-negative breast cancer that has gotten worse after previous treatments.
Guangzhou, GuangdongAges 18–70 - NCT06868277RecruitingPhase 3
Comparing two drugs for first-line treatment of advanced lung cancer
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
La Mesa, CaliforniaAges 18 years+ - NCT06866262RecruitingPhase 1/Phase 2
Inulin gel with immunotherapy for advanced kidney cancer
This trial tests whether adding an inulin gel to standard immunotherapy (ipilimumab and nivolumab) can help treat kidney cancer that has spread or cannot be removed. It is for people who have not had prior treatment for advanced disease.
Ann Arbor, MichiganAges 18 years+ - NCT06811116RecruitingPhase 1/Phase 2
Sapanisertib plus cabozantinib for advanced liver cancer
This trial studies a combination of two drugs for advanced liver cancer with a specific gene change. The goal is to see if adding sapanisertib to the usual cabozantinib treatment helps people live longer without their cancer growing.
Irvine, CaliforniaAges 18 years+ - NCT06791850Recruiting
Home heart failure support for rural patients and caregivers
This trial tests a home-based palliative care program for people with advanced heart failure living in rural areas and their caregivers. It aims to improve quality of life and reduce symptoms.
Morgantown, West VirginiaAges 45–80 - NCT06771544RecruitingPhase 2
Cyclophosphamide and pembrolizumab for advanced melanoma
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
Orange, CaliforniaAges 18 years+ - NCT06765317RecruitingPhase 2
Glofitamab therapy for older adults with diffuse large B-cell lymphoma
This trial tests a new combination therapy using glofitamab for people aged 65 or older with diffuse large B-cell lymphoma who have not received prior treatment. The goal is to see if this approach is safe and effective for patients who are considered too frail for standard therapies.
Basking Ridge, New JerseyAges 65–80 - NCT06742723RecruitingPhase 3
Study of baxdrostat and dapagliflozin for kidney disease and high blood pressure
This trial tests if combining baxdrostat with dapagliflozin helps protect kidney function and reduce heart risks in people with chronic kidney disease and high blood pressure. It's for adults who are already taking standard blood pressure medications.
Fairhope, AlabamaAges 18 years+ - NCT06745076RecruitingPhase 2
Personalized chemotherapy reduction for advanced Hodgkin lymphoma
This trial tests a personalized approach to using a blood test (ctDNA) to decide how much chemotherapy you need. If you have advanced Hodgkin lymphoma, this study might let you have less chemo if the blood test shows a strong response early on, potentially reducing side effects.
Irvine, CaliforniaAges 18 years+ - NCT06731270RecruitingPhase 2
Diclofenac for advanced lung cancer on immunotherapy
This trial tests whether adding the anti-inflammatory drug diclofenac can help people with advanced non-small cell lung cancer whose tumors are growing while on a single immunotherapy drug. You must have been on immunotherapy for at least 12 weeks and have a growing tumor, but your doctor does not plan to change your treatment right away.
Atlanta, GeorgiaAges 18 years+ - NCT06696768RecruitingPhase 1
New drug plus standard chemotherapy for advanced colorectal cancer
This trial combines a new experimental drug (emavusertib) with standard chemotherapy (FOLFOX plus bevacizumab) for people with stage IV colorectal cancer who have not yet received chemotherapy. The goal is to see if the combination is safe and effective, potentially offering a new first-line treatment option.
Gainesville, FloridaAges 18 years+ - NCT06693830Recruiting
Blood test guided treatment for newly diagnosed DLBCL
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
New York, New YorkAges 18 years+ - NCT06671691Enrolling by invitationPhase 1
Single-dose radiation for low-risk breast cancer
This trial tests a single, high-precision dose of radiation to the tumor instead of standard surgery or multiple radiation sessions. It is for women with a small, low-risk breast cancer who cannot or choose not to have surgery.
Palma, Balearic IslandsAges Any age - NCT06204991RecruitingPhase 1
T-cell therapy for advanced melanoma
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
HerlevAges 18–75 - NCT06605833Enrolling by invitation
Heart health after immunotherapy for melanoma
This study looks at heart health in people who have finished immunotherapy for melanoma. It uses MRI scans to check for any heart problems that may have developed after treatment.
LondonAges 18 years+ - NCT06552234RecruitingPhase 2
Study of repotrectinib for older or frail patients with ROS1-positive lung cancer
This trial tests an oral targeted therapy called repotrectinib in people with advanced non-small cell lung cancer (NSCLC) that has a change in the ROS1 gene. It is designed for patients who are either 70 or older, or have a lower performance status (ECOG 2 or higher), meaning they may be more frail or have more symptoms. The goal is to see if repotrectinib can help shrink or control the cancer.
Aix-en-Provence, Bouches Du RhôneAges 18 years+ - NCT06535568Recruiting
Comparing one vs two blood thinners after heart artery balloon treatment
This trial tests whether taking just one blood thinner (clopidogrel) is as safe and effective as taking two (clopidogrel plus aspirin) for older adults or people at high bleeding risk who have had a drug-coated balloon procedure to open blocked heart arteries.
Milan, MIAges Any age - NCT06498648RecruitingPhase 1/Phase 2
Abemaciclib with gemcitabine for soft tissue sarcoma
This trial tests whether adding the targeted drug abemaciclib to standard chemotherapy (gemcitabine) works better against certain soft tissue sarcomas. It is for people whose tumors have a normal Rb gene, which may help the drug work.
Houston, TexasAges 18 years+ - NCT06508775Recruiting
Long-term checkup for Miltenyi cell therapy patients
This study is a long-term check-in for people who received a special type of immunotherapy (CAR T cells) made by Miltenyi. It helps researchers see how you're doing over time after your treatment.
BerlinAges Any age - NCT06262321RecruitingPhase 2
Chest Radiation for Advanced Lung Cancer at High Risk of Symptoms
This study tests whether giving radiation to tumors in the chest soon after starting systemic therapy can help prevent symptoms like pain, trouble breathing, or bleeding. It is for people with advanced non-small cell lung cancer that does not have certain gene changes and has high-risk tumors in the chest.
Rochester, New YorkAges 18 years+ - NCT06512207Recruiting
Hormone therapy plus immunotherapy for advanced lung cancer
This trial tests a combination of hormone therapy (androgen deprivation) and an immunotherapy drug (anti-PD-1) for men with advanced lung cancer. It aims to see if this combination slows cancer growth better than standard treatments.
Zhengzhou, HenanAges 60 years+ - NCT06495125RecruitingPhase 2
Study of three drugs for a type of advanced lung cancer
This trial tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) for people with advanced lung adenocarcinoma that has a specific gene mutation (LKB1) and has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this new combination can shrink tumors or slow cancer growth.
Atlanta, GeorgiaAges 18 years+
Hear when a new High Grade Glioma (III or IV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high grade glioma (iii or iv)?
- Yes. Clin2 currently lists 1,259 recruiting high grade glioma (iii or iv) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high grade glioma (iii or iv) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high grade glioma (iii or iv) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.